Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Singh (Manchester, United Kingdom), J. Virchow (Rostock, Germany), W. Canonica (Milan, Italy), S. Corre (Parma, Italy), F. Zuccaro (Parma, Italy), M. Kots (Parma, Italy), A. Vele (Parma, Italy), G. Georges (Parma, Italy), S. Petruzzelli (Parma, Italy). Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies. 3779

Member's Comments

No comment yet.

Related content which might interest you: CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 CAPTAIN: Effects of smoking status on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD Source: International Congress 2017 – COPD management Year: 2017 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses Source: ERJ Open Res, 4 (2) 00119-2017; 10.1183/23120541.00119-2017 Year: 2018 Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies Source: Eur Respir J, 58 (3) 2004233; 10.1183/13993003.04233-2020 Year: 2021 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Self-titration of inhaled corticosteroid and ß2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial Source: Eur Respir J, 56 (4) 2000170; 10.1183/13993003.00170-2020 Year: 2020 Factors influencing LAMA addition to COPD patients receiving ICS/LABA in clinical practice-RETRIEVE study. Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Retrospective review of studies shows that patients receiving salmeterol plus ICS have fewer serious asthma exacerbations vs patients on ICS alone, regardless of ethnic origin Source: Eur Respir J 2005; 26: Suppl. 49, 429s Year: 2005 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Predictive factors for asthma control according to ACQ5 in asthma patients treated with budesonide/formoterol maintenance and reliever therapy. Results from the EuroSMART study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010